<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032002</url>
  </required_header>
  <id_info>
    <org_study_id>2018/349/HP</org_study_id>
    <nct_id>NCT04032002</nct_id>
  </id_info>
  <brief_title>Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema</brief_title>
  <acronym>MONOBRAD</acronym>
  <official_title>Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare the gene expression of B1 and / or B2 monocyte receptors between&#xD;
      patients with hereditary bradykinetic angioedema and control subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the gene expression of B1 and / or B2 monocyte receptors</measure>
    <time_frame>Day 1</time_frame>
    <description>compare between patients with hereditary bradykinetic angioedema and control subjects.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hereditary Bradykinetic Angioedema</condition>
  <arm_group>
    <arm_group_label>Patients hereditary bradykinetic angioedema</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Explorations</intervention_name>
    <description>On Day 1 vascular fonctions explorations performed</description>
    <arm_group_label>Patients hereditary bradykinetic angioedema</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>On Day 1 35ml taken</description>
    <arm_group_label>Patients hereditary bradykinetic angioedema</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (patients):&#xD;
&#xD;
          -  Patient with inherited bradykinic angioedema due to quantitative or qualitative&#xD;
             C1-inhibitor deficiencies, regardless of the frequency or severity of seizures and&#xD;
             regardless of their background treatment, with the following diagnostic criteria:&#xD;
&#xD;
               -  C1-inhibitor rate &lt;50% of normal&#xD;
&#xD;
               -  Repeated episodes characteristic of bradykinic angioedema&#xD;
&#xD;
               -  Hereditary nature of the disease.&#xD;
&#xD;
          -  Person who read and understood the newsletter and signed the consent form&#xD;
&#xD;
          -  Person affiliated with a social security scheme&#xD;
&#xD;
          -  Effective contraception in women of childbearing age (negative pregnancy test). For&#xD;
             postmenopausal women, a confirmatory diagnosis should be obtained (amenorrhea for at&#xD;
             least 12 months before the inclusion visit).&#xD;
&#xD;
        Inclusion Criteria (volunteers):&#xD;
&#xD;
          -  Person affiliated with a social security scheme&#xD;
&#xD;
          -  Person who read and understood the newsletter and signed the consent form&#xD;
&#xD;
          -  Effective contraception in women of childbearing age (negative pregnancy test). For&#xD;
             postmenopausal women, a confirmation diagnosis should be obtained (amenorrhea for at&#xD;
             least 12 months before the inclusion visit)&#xD;
&#xD;
        Exclusion Criteria (patients):&#xD;
&#xD;
          -  Angioedema crisis less than 1 month old&#xD;
&#xD;
          -  Chronic inflammatory disease such as rheumatoid arthritis or Crohn's disease.&#xD;
&#xD;
          -  Acute infection in progress, with or without anti-infectious treatment&#xD;
&#xD;
          -  Contraindication to the use of trinitrin:&#xD;
&#xD;
               -  Hypersensitivity to nitrates or to any of the excipients&#xD;
&#xD;
               -  shock, severe hypotension,&#xD;
&#xD;
               -  obstructive cardiomyopathy,&#xD;
&#xD;
               -  inferior court inferior myocardial infarction with right ventricular extension,&#xD;
                  except in case of evidence of left ventricular failure,&#xD;
&#xD;
               -  intracranial hypertension,&#xD;
&#xD;
               -  patient treated with sildenafil&#xD;
&#xD;
          -  Pregnant or parturient or breastfeeding woman or lack of proven contraception&#xD;
&#xD;
          -  Person deprived of liberty by an administrative or judicial decision or person placed&#xD;
             under the protection of justice / sub-tutorship or curatorship&#xD;
&#xD;
          -  Patient participating or having participated in another therapeutic trial within one&#xD;
             week.&#xD;
&#xD;
        Exclusion Criteria (volunteers)&#xD;
&#xD;
          -  Chronic inflammatory disease such as rheumatoid arthritis or Crohn's disease.&#xD;
&#xD;
          -  Acute infection in progress, with or without anti-infectious treatment&#xD;
&#xD;
          -  Contraindication to the use of trinitrin:&#xD;
&#xD;
               -  Hypersensitivity to nitrates or to any of the excipients&#xD;
&#xD;
               -  shock, severe hypotension,&#xD;
&#xD;
               -  obstructive cardiomyopathy,&#xD;
&#xD;
               -  inferior court inferior myocardial infarction with right ventricular extension,&#xD;
                  except in case of evidence of left ventricular failure,&#xD;
&#xD;
               -  intracranial hypertension,&#xD;
&#xD;
               -  patient treated with sildenafil&#xD;
&#xD;
          -  Pregnant or parturient or breastfeeding woman or lack of proven contraception&#xD;
&#xD;
          -  Person deprived of liberty by an administrative or judicial decision or person placed&#xD;
             under the protection of justice / sub-tutorship or curatorship&#xD;
&#xD;
          -  Person participating or having participated in another therapeutic trial within one&#xD;
             week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DRCI</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MALLET</last_name>
      <phone>0232888265</phone>
      <email>secretariat.drc@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume ARMENGOL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

